Recommended Liver Test Monitoring During Tigecycline Therapy
Tigecycline, an IV glycylcycline antibiotic for complicated infections, requires liver function tests (LFTs) at baseline before starting therapy. The prescribing information recommends monitoring LFTs weekly during treatment, particularly in patients with elevated baseline values or risk factors like hepatic impairment.[1]
Why Weekly Monitoring for Tigecycline?
Tigecycline can cause elevated liver enzymes (ALT, AST, alkaline phosphatase) in up to 15-20% of patients, with rare cases of severe hepatic injury. Weekly checks allow early detection, as elevations often appear within the first 1-2 weeks of the typical 5-14 day course. Discontinue if transaminases exceed 5x upper limit of normal.[1][2]
Adjustments for High-Risk Patients
- Hepatic impairment: No dose change needed for Child-Pugh A/B, but avoid in Child-Pugh C; monitor LFTs more frequently (every 3-5 days) if baseline abnormalities exist.
- Concomitant hepatotoxins (e.g., other antibiotics, statins): Increase to twice-weekly testing.
- Duration >14 days: Continue weekly, with clinical judgment for extension.[1][3]
What Tests to Run and Normal Ranges
Standard panel: ALT, AST, bilirubin, alkaline phosphatase, prothrombin time.
- ALT/AST: <40-50 U/L typical upper limit.
- Total bilirubin: <1.2 mg/dL.
Tigecycline-related rises are usually asymptomatic and reversible post-treatment.[2]
Comparison to Other Antibiotics
| Antibiotic | Suggested LFT Interval | Key Difference from Tigecycline |
|------------|--------------------------|--------------------------------|
| Vancomycin | Baseline + weekly if renal issues | Less hepatotoxicity; focuses on trough levels. |
| Linezolid | Baseline only, unless prolonged use | Rare liver effects; no routine weekly mandate. |
| Daptomycin | Baseline + as clinically indicated | Minimal hepatic risk. |
| Meropenem | Baseline in liver disease | Carbapenems rarely need repeats unless cholestasis.[3] |
Clinical Outcomes and Real-World Data
In trials, 2-3% discontinued tigecycline due to liver issues. Post-marketing reports note cholestatic hepatitis in <1%, often with other drugs. Recovery occurs in 90%+ after stopping.[1][4]
Sources:
[1]: Tygacil (tigecycline) Prescribing Information - Pfizer
[2]: FDA Adverse Event Reporting System (FAERS) Summary
[3]: IDSA Guidelines on Antimicrobial Monitoring
[4]: DrugPatentWatch.com - Tigecycline Patent Status